AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Gi cocktail3/1/2023 ![]() ![]() Similar results were published from Chinese studies carried out in the early weeks and months of the pandemic. They concluded this was not a “negligible” amount and noted that many patients with GI symptoms (35 out of 42) did not actual present a major respiratory symptom: the cough. Researchers studied all patients admitted to the General Hospital of Crema in Italy with suspected Covid-19 between 21 February and 13 March 2020 and found that around 10% (42 out of 411) reported GI symptoms. The existence of GI symptoms became evident early in the pandemic. One company leading the way in this area is Seattle-based Lumen Bioscience, which develops edible spirulina-based drugs that can directly target the GI tract.Įxploring overlooked Covid-19 GI symptoms Meaning the resulting GI symptoms, which are viewed as less common and ‘non-specific’ by the UK Government, including diarrhoea, nausea and vomiting, may actually be an important indicator of SARS-CoV-2 infection and Covid-19.Ĭonsequently, there is a need to think about Covid-19 as more than a respiratory disease and find ways to treat this GI component of the disease. However, although the respiratory system may be the most well-known SARS-CoV-2 entry point into the body, research suggests the gastrointestinal tract (GI) tract is an alternative route for infection. This is no surprise given the virus that causes Covid-19 is known as SARS-CoV-2 and SARS is an acronym for severe acute respiratory syndrome. This is because these respiratory symptoms have been found to be the most related to Covid-19 infection. If you want to book a free Covid-19 test in the UK, you must have at least one of three symptoms: a high temperature, a new, continuous cough and a change in your taste or smell. The "GI Cocktail" concoction may not be necessary.Lumen are investigating if its spirulina-based drug can treat the GI symptoms of Covid-19. ![]() In conclusion, the addition of Donnatal or Donnatal + lidocaine to an antacid did not relieve dyspepsia better than plain antacid. There was no statistically significant difference in pain relief between the three groups on univariate analysis or multivariable regression. Group 1 had a 25 +/- 27 mm mean (+/- SD), decrease in pain Group 2, 23 +/- 22 mm decrease and Group 3, 24 +/- 26 mm decrease. There was no statistically significant difference between the groups in terms of age, gender, GI history, previous antacid use, or initial degree of pain. One hundred thirteen subjects (113) completed the protocol: Group 1 (N = 38) Group 2 (N = 37) Group 3 (N = 38). One hundred twenty patients were enrolled between July and December 2000. VAS change in the three groups was compared using multivariable regression, controlling for pretreatment VAS, study drug, previous antacid use, and gastrointestinal (GI) history. A 13-mm difference in VAS was considered clinically significant. Change in VAS was the primary study endpoint. Patients rated their discomfort on a Visual Analog Scale (VAS) immediately before receiving the medication and 30 min later. Patients were randomly assigned to receive one of the three medication combinations. The study was a prospective, randomized, double-blinded trial comparing antacid (group 1) antacid + Donnatal (group 2) antacid + Donnatal + viscous lidocaine (group 3) for acute treatment of dyspepsia in the ED. This study compared three combinations commonly given for dyspepsia. Several combinations are used, but the most effective has not yet been determined. The "GI Cocktail" is a mixture of medications often given in the Emergency Department (ED) for dyspepsia symptoms. ![]()
0 Comments
Read More
Leave a Reply. |